Claims for Patent: 10,420,841

Summary for Patent: 10,420,841

Title:	Ceftolozane antibiotic compositions
Abstract:	This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
Inventor(s):	Terracciano; Joseph (Concord, MA), Damour; Nicole Miller (Belmont, MA), Jiang; Chun (Hillsborough, CA), Fogliato; Giovanni (Barzana, IT), Donadelli; Giuseppe Alessandron (Lodi, IT), Resemini; Dario (Milan, IT)
Assignee:	Merck, Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	15/844,961
Patent Claims:	1. A method for treating an infection selected from the group consisting of a complicated intra-abdominal infection and a complicated urinary tract infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% of a compound of formula (III) ##STR00018## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight. 2. The method of claim 1, wherein the infection is a complicated intra-abdominal infection. 3. The method of claim 1, wherein the infection is a complicated urinary tract infection. 4. The method of claim 1, wherein the composition contains less than 0.1% of the compound of formula (III) relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 5. The method of claim 1, wherein the composition contains less than 0.03% of the compound of formula (III) relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 6. The method of claim 1, wherein the amount of ceftolozane active in the pharmaceutical composition is 1,000 mg and the amount of tazobactam active in the pharmaceutical composition is 500 mg. 7. The method of claim 1, wherein the amount of ceftolozane active in the pharmaceutical composition is 2,000 mg and the amount of tazobactam active in the pharmaceutical composition is 1,000 mg. 8. The method of claim 1, wherein the composition comprises 1,147 mg ceftolozane sulfate and 537 mg tazobactam sodium. 9. The method of claim 1, wherein the composition is provided in a unit dosage form. 10. The method of claim 1, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by parenteral administration. 11. The method of claim 1, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 12. The method of claim 2, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 13. The method of claim 3, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 14. A method for treating an infection selected from the group consisting of a complicated intra-abdominal infection and a complicated urinary tract infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% of the compound of formula (III) ##STR00019## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, and less than 1.5% of a compound of formula (IV) ##STR00020## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 3 months at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight. 15. The method of claim 14, wherein the infection is a complicated intra-abdominal infection. 16. The method of claim 14, wherein the infection is a complicated urinary tract infection. 17. The method of claim 14, wherein the composition contains less than 0.05% of the compound of formula (III) relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 3 months at a temperature of 25.degree. C. and at a relative humidity of 60%. 18. The method of claim 14, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 19. A method for treating an infection selected from the group consisting of a complicated intra-abdominal infection and a complicated urinary tract infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% relative to ceftolozane sulfate of the compound having a mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight. 20. The method of claim 19, wherein the infection is a complicated intra-abdominal infection. 21. The method of claim 19, wherein the infection is a complicated urinary tract infection. 22. The method of claim 19, wherein the composition contains less than 0.1% relative to ceftolozane sulfate of the compound with the mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 23. The method of claim 19, wherein the composition contains less than 0.03% relative to ceftolozane sulfate of the compound with the mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 1 month at a temperature of 25.degree. C. and at a relative humidity of 60%. 24. The method of claim 19, wherein the amount of ceftolozane active in the pharmaceutical composition is 1,000 mg and the amount of tazobactam active in the pharmaceutical composition is 500 mg. 25. The method of claim 19, wherein the amount of ceftolozane active in the pharmaceutical composition is 2,000 mg and the amount of tazobactam active in the pharmaceutical composition is 1,000 mg. 26. The method of claim 19, wherein the composition comprises 1,147 mg ceftolozane sulfate and 537 mg tazobactam sodium. 27. The method of claim 19, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion. 28. A method for treating an infection selected from the group consisting of a complicated intra-abdominal infection and a complicated urinary tract infection in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and tazobactam sodium, said composition comprising less than 0.15% relative to ceftolozane sulfate of a compound having a mass spectra depicted in FIG. 14, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, and less than 1.5% of a compound of formula (IV): ##STR00021## relative to ceftolozane sulfate, as determined by high performance liquid chromatography (HPLC) at a wavelength of 254 nm, when stored as a solid for 3 months at a temperature of 25.degree. C. and at a relative humidity of 60%, wherein the ceftolozane sulfate and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight. 29. The method of claim 28, wherein the infection is a complicated intra-abdominal infection. 30. The method of claim 28, wherein the infection is a complicated urinary tract infection. 31. The method of claim 28, wherein the pharmaceutical composition is dissolved in a pharmaceutically acceptable carrier and administered by intravenous infusion.